In a June 26 press release, ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced it has advanced antibody candidates against a pair of targets suspected to cause neurodegenerative disease to the second phase of its discovery platform. The targets are "aggregated, toxic oligomers of alpha-synuclein, implicated in the development of Parkinson's disease (PD), as well as TDP43 (TAR DNA binding protein), implicated in the development of ALS [amyotrophic lateral sclerosis],"according to the release.
The company's lead candidate, PMN310, targets Alzheimer's disease, also a prominent neurodegenerative indication.
In the announcement, ProMIS' chief science officer, Dr. Neil Cashman, explained the company's two-phase discovery platform.
"The first stage involves predicting novel epitope targets and using these to generate large numbers of candidate antibodies. The second stage is to validate selectivity, functional activity, and select the best leads," Cashman stated.
The press release notes "hundreds of monoclonal antibodies have been generated against these predicted disease-specific epitopes and ProMIS has now begun the validation and prioritization process to select therapeutic candidates displaying an ideal, highly selective product profile against these targets."
Noting progression into the second phase of discovery complies with the company's corporate strategy, ProMIS executive chairman Gene Williams stated, "We are actively pursuing discussions with large pharma regarding partnering of these two new toxic oligomer programs."
Read what other experts are saying about:
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
